As the sun sets on another intensive day at the cancer ward, the breakthroughs in melanoma treatment, particularly with the advent of immune checkpoint inhibitor (ICI) therapy, offer a glimmer of hope on the horizon. This innovative treatment has significantly improved the survival rates of patients suffering from advanced melanoma, a previously grim diagnosis. But not without its trade-offs: a new study delves into the complexities of the symptom burden carried by patients undergoing ICI therapy, shedding light on their often unpredictable impact on health-related quality of life (HRQoL) and functionality.

In a meticulous effort to understand the nuances of the patient experience, a recent article published in the “Seminars in Oncology Nursing” has surfaced the results of a thought-provoking study conducted by a team of dedicated researchers from the noted institutions of The University of Texas Health Science Center at Houston and the University of Texas MD Anderson Cancer Center (Jackson-Carroll et al., 2024). For 19 patients battling the tyrannies of advanced melanoma, the researchers employed a descriptive exploratory content analysis, coupled with semistructured interviews following quantitative data collection through patient-reported outcome (PRO) instruments.

The findings, as reported in the study entitled “The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy,” are both informative and evocative. By utilizing the Modified MD Anderson Symptom Inventory and the Functional Assessment of Cancer Therapy-Melanoma, the research team captured a rich tapestry of patient stories that reflect a heterogenous and idiosyncratic symptom landscape ranging from distress and fatigue to rash, pain, and gastrointestinal discomfort. The DOI for this groundbreaking work is 10.1016/j.soncn.2023.151574.

Participants shared deeply personal encounters with symptoms like distress (84%), fatigue (68%), skin changes (53%), pain (30%), diarrhea (30%), itching (26%), and shortness of breath (21%). These were symptoms that did not just affect their bodies but rippled into their emotional and social worlds, impacting mood (47%), relations (26%), and activities (21%)—integral facets of HRQoL.

The research, however, shows a silver lining where a significant number of patients (79%) experienced no physical interference in their lives, suggesting that there may be adaptive capabilities or resourceful strategies in place that help some patients cope better than others. Emotional resilience amid medical uncertainty, it seems, is an unsung narrative in the cancer journey. This is highlighted by the fact that while a staggering 68% of the patients reported grappling with uncertainty, there still shone a hopeful attitude toward ICI therapy (58%) and a positive expectation of successful outcomes (53%).

The insights from this qualitative exploration underscore the critical role of transparent communication surrounding the diagnosis, prognosis, treatment options, and potential outcomes of the disease. Such communication must acknowledge the uncertainties that are inherently part of the journey with advanced melanoma and its treatment regimen.

The implications of this study are wide-reaching. For healthcare professionals, especially nurses who are often at the front lines of patient care, the findings advocate for the use of validated PRO instruments to document and comprehend the patients’ symptom experience thoroughly. Tools such as the ones utilized in this study equip healthcare workers to capture the nuanced symptomatology experienced by patients, thus enhancing patient-centered care and tailored supportive strategies.

Furthermore, the study calls attention to the importance of understanding the full spectrum of experiences of patients with advanced melanoma, beyond the clinical outcomes and survival rates. It highlights the need for supportive care tailored to the unique needs of each patient, addressing not only the physical but also the emotional, social, and psychological challenges they face during and beyond the treatment.

This pioneering study, encapsulated in the astutely selected journal, is a testament to the ever-evolving landscape of oncology nursing. As such, it reveals a holistic perspective on the patient experience that is as inextricable as it is invaluable, ultimately contributing to more compassionate and effective treatment pathways for those with advanced melanoma on ICI therapy.


1. Immune checkpoint inhibitors
2. Advanced melanoma treatment
3. Patient-reported outcomes
4. Quality of life in cancer care
5. Symptom burden in oncology


1. Jackson-Carroll, N.N., Johnson, C.C., Tawbi, H.H., Wang, X.S., & Whisenant, M.M. (2024). The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy. Seminars in Oncology Nursing, 151574. DOI: 10.1016/j.soncn.2023.151574
2. Postow, M.A., Callahan, M.K., & Wolchok, J.D. (2015). Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology, 33(17), 1974-1982. DOI: 10.1200/JCO.2014.59.4358
3. Weber, J.S., D’Angelo, S.P., Minor, D., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375-384. DOI: 10.1016/S1470-2045(15)70076-8
4. Schadendorf, D., Hodi, F.S., Robert, C., et al. (2015). Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of Clinical Oncology, 33(17), 1889-1894. DOI: 10.1200/JCO.2014.56.2736
5. Falchook, G.S., Long, G.V., Kurzrock, R., et al. (2013). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet, 379(9829), 1893-1901. DOI: 10.1016/S0140-6736(12)60398-5

By acknowledging and addressing the full symptom experience of advanced melanoma patients, the healthcare community can strive toward not just prolonging life, but also enhancing its quality, even amidst the adversity of a persistent and challenging disease.